This initial dose-escalation study demonstrated a favorable safety ... Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042 ...

The phase Ib dose escalation study is evaluating ... to focus on the development of PH-762 for skin cancers in the United States. Phio Pharmaceuticals Corp. price-consensus-chart | Phio ...

- Conducted under U.S. FDA-cleared IND - Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Connext, a clinical stage ...

The clinical trial is being conducted at multiple centers and is an open-label, dose-escalation study which is designed to evaluate the safety, tolerability and early effectiveness of the new ...

This initial dose-escalation ... No drug-related serious adverse events (SAEs) were reported One NSCLC patient from the 10 mg/kg cohort had an unconfirmed partial response and remains on study ...

This initial dose-escalation study demonstrated a favorable safety ... “BDC-3042 deserves rapid development, especially given its enormous commercial potential. We are launching a process ...

This initial dose-escalation study demonstrated a favorable safety profile ... candidates are built on the Company's deep expertise in myeloid biology and cancer drug development. The Company's ...